APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Multivalent Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174014880326 December 2025197 pages

Choose your research edition.

Industry ResearchMultivalent Vaccines Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Multivalent Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Vaccines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Multivalent Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multivalent Vaccines include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multivalent Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multivalent Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multivalent Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multivalent Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Multivalent Vaccines Segment by Company

Bavarian Nordic (Denmark)

CSL Limited (Australia)

Daiichi Sankyo (Japan)

Emergent BioSolutions, Inc(US)

GlaxoSmithKline, plc (U.K.)

MedImmune, LLC (US)

Mitsubishi Tanabe Pharma Corporation (Japan)

Panacea Biotec (India)

Protein Sciences Corporation (US)

Serum Institute of India Pvt. Ltd. (India)

Astellas Pharma Inc. (Japan)

Pfizer, Inc(US)

Merck & Co., Inc(US)

Johnson & Johnson (US)

Sanofi Pasteur SA (France)

Multivalent Vaccines Segment by Type

Toxoid Vaccines

Live Attenuated Vaccines

Conjugate Vaccines

Inactivated and Subunit Vaccines

Recombinant Vaccines

Multivalent Vaccines Segment by Application

Pediatrics

Adults

Multivalent Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Multivalent Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Multivalent Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Multivalent Vaccines Industry Trends Table 2. Multivalent Vaccines Industry Drivers Table 3. Multivalent Vaccines Industry Opportunities and Challenges Table 4. Multivalent Vaccines Industry Restraints Table 5. Global Multivalent Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Multivalent Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Multivalent Vaccines Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Multivalent Vaccines Sales Market Share by Manufacturers Table 9. Global Multivalent Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Multivalent Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Multivalent Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Multivalent Vaccines Manufacturers, Product Type & Application Table 13. Global Multivalent Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Multivalent Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Toxoid Vaccines Table 17. Major Manufacturers of Live Attenuated Vaccines Table 18. Major Manufacturers of Conjugate Vaccines Table 19. Major Manufacturers of Inactivated and Subunit Vaccines Table 20. Major Manufacturers of Recombinant Vaccines Table 21. Global Multivalent Vaccines Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 23. Global Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 24. Global Multivalent Vaccines Sales Market Share by Type (2021-2026) Table 25. Global Multivalent Vaccines Sales Market Share by Type (2027-2032) Table 26. Global Multivalent Vaccines Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Multivalent Vaccines Revenue by Type (2021-2026) & (W Units) Table 28. Global Multivalent Vaccines Revenue by Type (2027-2032) & (W Units) Table 29. Global Multivalent Vaccines Revenue Market Share by Type (2021-2026) Table 30. Global Multivalent Vaccines Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Pediatrics Table 32. Major Manufacturers of Adults Table 33. Global Multivalent Vaccines Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 35. Global Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 36. Global Multivalent Vaccines Sales Market Share by Application (2021-2026) Table 37. Global Multivalent Vaccines Sales Market Share by Application (2027-2032) Table 38. Global Multivalent Vaccines Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Multivalent Vaccines Revenue by Application (2021-2026) & (W Units) Table 40. Global Multivalent Vaccines Revenue by Application (2027-2032) & (W Units) Table 41. Global Multivalent Vaccines Revenue Market Share by Application (2021-2026) Table 42. Global Multivalent Vaccines Revenue Market Share by Application (2027-2032) Table 43. Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Multivalent Vaccines Sales by Region (2021-2026) & (W Units) Table 45. Global Multivalent Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Multivalent Vaccines Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Multivalent Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 50. North America Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 51. Europe Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 53. Europe Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 60. Global Multivalent Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Multivalent Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Multivalent Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Multivalent Vaccines Revenue Market Share by Region (2021-2026) Table 64. Global Multivalent Vaccines Revenue Market Share by Region (2027-2032) Table 65. Bavarian Nordic (Denmark) Company Information Table 66. Bavarian Nordic (Denmark) Business Overview Table 67. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio Table 69. Bavarian Nordic (Denmark) Recent Development Table 70. CSL Limited (Australia) Company Information Table 71. CSL Limited (Australia) Business Overview Table 72. CSL Limited (Australia) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. CSL Limited (Australia) Multivalent Vaccines Product Portfolio Table 74. CSL Limited (Australia) Recent Development Table 75. Daiichi Sankyo (Japan) Company Information Table 76. Daiichi Sankyo (Japan) Business Overview Table 77. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio Table 79. Daiichi Sankyo (Japan) Recent Development Table 80. Emergent BioSolutions, Inc(US) Company Information Table 81. Emergent BioSolutions, Inc(US) Business Overview Table 82. Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio Table 84. Emergent BioSolutions, Inc(US) Recent Development Table 85. GlaxoSmithKline, plc (U.K.) Company Information Table 86. GlaxoSmithKline, plc (U.K.) Business Overview Table 87. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio Table 89. GlaxoSmithKline, plc (U.K.) Recent Development Table 90. MedImmune, LLC (US) Company Information Table 91. MedImmune, LLC (US) Business Overview Table 92. MedImmune, LLC (US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. MedImmune, LLC (US) Multivalent Vaccines Product Portfolio Table 94. MedImmune, LLC (US) Recent Development Table 95. Mitsubishi Tanabe Pharma Corporation (Japan) Company Information Table 96. Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview Table 97. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio Table 99. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development Table 100. Panacea Biotec (India) Company Information Table 101. Panacea Biotec (India) Business Overview Table 102. Panacea Biotec (India) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Panacea Biotec (India) Multivalent Vaccines Product Portfolio Table 104. Panacea Biotec (India) Recent Development Table 105. Protein Sciences Corporation (US) Company Information Table 106. Protein Sciences Corporation (US) Business Overview Table 107. Protein Sciences Corporation (US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio Table 109. Protein Sciences Corporation (US) Recent Development Table 110. Serum Institute of India Pvt. Ltd. (India) Company Information Table 111. Serum Institute of India Pvt. Ltd. (India) Business Overview Table 112. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio Table 114. Serum Institute of India Pvt. Ltd. (India) Recent Development Table 115. Astellas Pharma Inc. (Japan) Company Information Table 116. Astellas Pharma Inc. (Japan) Business Overview Table 117. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio Table 119. Astellas Pharma Inc. (Japan) Recent Development Table 120. Pfizer, Inc(US) Company Information Table 121. Pfizer, Inc(US) Business Overview Table 122. Pfizer, Inc(US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Pfizer, Inc(US) Multivalent Vaccines Product Portfolio Table 124. Pfizer, Inc(US) Recent Development Table 125. Merck & Co., Inc(US) Company Information Table 126. Merck & Co., Inc(US) Business Overview Table 127. Merck & Co., Inc(US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio Table 129. Merck & Co., Inc(US) Recent Development Table 130. Johnson & Johnson (US) Company Information Table 131. Johnson & Johnson (US) Business Overview Table 132. Johnson & Johnson (US) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Johnson & Johnson (US) Multivalent Vaccines Product Portfolio Table 134. Johnson & Johnson (US) Recent Development Table 135. Sanofi Pasteur SA (France) Company Information Table 136. Sanofi Pasteur SA (France) Business Overview Table 137. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio Table 139. Sanofi Pasteur SA (France) Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Multivalent Vaccines Distributors List Table 143. Multivalent Vaccines Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Multivalent Vaccines Product Image Figure 2. Global Multivalent Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Multivalent Vaccines Sales (2021-2032) & (W Units) Figure 5. Global Multivalent Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Multivalent Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Toxoid Vaccines Image Figure 9. Live Attenuated Vaccines Image Figure 10. Conjugate Vaccines Image Figure 11. Inactivated and Subunit Vaccines Image Figure 12. Recombinant Vaccines Image Figure 13. Global Multivalent Vaccines Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Multivalent Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Multivalent Vaccines Sales Market Share by Type (2021-2032) Figure 16. Global Multivalent Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Multivalent Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Multivalent Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Pediatrics Image Figure 20. Adults Image Figure 21. Global Multivalent Vaccines Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Multivalent Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Multivalent Vaccines Sales Market Share by Application (2021-2032) Figure 24. Global Multivalent Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Multivalent Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Multivalent Vaccines Revenue Market Share by Application (2021-2032) Figure 27. North America Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Multivalent Vaccines Sales Market Share by Country (2021-2032) Figure 29. U.S. Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Multivalent Vaccines Sales Market Share by Country (2021-2032) Figure 34. Germany Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Multivalent Vaccines Sales Market Share by Country (2021-2032) Figure 41. China Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Multivalent Vaccines Sales Market Share by Country (2021-2032) Figure 49. Brazil Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Multivalent Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Multivalent Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Multivalent Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Figure 60. North America Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Figure 62. Europe Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Multivalent Vaccines Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Multivalent Vaccines Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Toxoid Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Recombinant Vaccines
Applications
  • Pediatrics
  • Adults
Companies covered
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • Daiichi Sankyo (Japan)
  • Emergent BioSolutions, Inc(US)
  • GlaxoSmithKline, plc (U.K.)
  • MedImmune, LLC (US)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Panacea Biotec (India)
  • Protein Sciences Corporation (US)
  • Serum Institute of India Pvt. Ltd. (India)
  • Astellas Pharma Inc. (Japan)
  • Pfizer, Inc(US)
  • Merck & Co., Inc(US)
  • Johnson & Johnson (US)
  • Sanofi Pasteur SA (France)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multivalent Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multivalent Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Multivalent Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Multivalent Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Multivalent Vaccines Market Dynamics
  1. 2.1 Multivalent Vaccines Industry Trends
  2. 2.2 Multivalent Vaccines Industry Drivers
  3. 2.3 Multivalent Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Vaccines Industry Restraints
3 Multivalent Vaccines Market by Manufacturers
  1. 3.1 Global Multivalent Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Multivalent Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Multivalent Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Multivalent Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multivalent Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Multivalent Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Multivalent Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multivalent Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multivalent Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multivalent Vaccines Tier 1, Tier 2, and Tier 3
4 Multivalent Vaccines Market by Type
  1. 4.1 Multivalent Vaccines Type Introduction
  2. 4.1.1 Toxoid Vaccines
  3. 4.1.2 Live Attenuated Vaccines
  4. 4.1.3 Conjugate Vaccines
  5. 4.1.4 Inactivated and Subunit Vaccines
  6. 4.1.5 Recombinant Vaccines
  7. 4.2 Global Multivalent Vaccines Sales by Type
  8. 4.2.1 Global Multivalent Vaccines Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Multivalent Vaccines Sales by Type (2021-2032)
  10. 4.2.3 Global Multivalent Vaccines Sales Market Share by Type (2021-2032)
  11. 4.3 Global Multivalent Vaccines Revenue by Type
  12. 4.3.1 Global Multivalent Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Multivalent Vaccines Revenue by Type (2021-2032)
  14. 4.3.3 Global Multivalent Vaccines Revenue Market Share by Type (2021-2032)
5 Multivalent Vaccines Market by Application
  1. 5.1 Multivalent Vaccines Application Introduction
  2. 5.1.1 Pediatrics
  3. 5.1.2 Adults
  4. 5.2 Global Multivalent Vaccines Sales by Application
  5. 5.2.1 Global Multivalent Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multivalent Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Multivalent Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Multivalent Vaccines Revenue by Application
  9. 5.3.1 Global Multivalent Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multivalent Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Multivalent Vaccines Revenue Market Share by Application (2021-2032)
6 Global Multivalent Vaccines Sales by Region
  1. 6.1 Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multivalent Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Multivalent Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Multivalent Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Multivalent Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Multivalent Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Multivalent Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Multivalent Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Multivalent Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Multivalent Vaccines Revenue by Region
  1. 7.1 Global Multivalent Vaccines Revenue by Region
  2. 7.1.1 Global Multivalent Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Multivalent Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Multivalent Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Multivalent Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Multivalent Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Multivalent Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Multivalent Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Multivalent Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Multivalent Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bavarian Nordic (Denmark)
  2. 8.1.1 Bavarian Nordic (Denmark) Company Information
  3. 8.1.2 Bavarian Nordic (Denmark) Business Overview
  4. 8.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
  6. 8.1.5 Bavarian Nordic (Denmark) Recent Developments
  7. 8.2 CSL Limited (Australia)
  8. 8.2.1 CSL Limited (Australia) Company Information
  9. 8.2.2 CSL Limited (Australia) Business Overview
  10. 8.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
  12. 8.2.5 CSL Limited (Australia) Recent Developments
  13. 8.3 Daiichi Sankyo (Japan)
  14. 8.3.1 Daiichi Sankyo (Japan) Company Information
  15. 8.3.2 Daiichi Sankyo (Japan) Business Overview
  16. 8.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
  18. 8.3.5 Daiichi Sankyo (Japan) Recent Developments
  19. 8.4 Emergent BioSolutions, Inc(US)
  20. 8.4.1 Emergent BioSolutions, Inc(US) Company Information
  21. 8.4.2 Emergent BioSolutions, Inc(US) Business Overview
  22. 8.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
  24. 8.4.5 Emergent BioSolutions, Inc(US) Recent Developments
  25. 8.5 GlaxoSmithKline, plc (U.K.)
  26. 8.5.1 GlaxoSmithKline, plc (U.K.) Company Information
  27. 8.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
  28. 8.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
  31. 8.6 MedImmune, LLC (US)
  32. 8.6.1 MedImmune, LLC (US) Company Information
  33. 8.6.2 MedImmune, LLC (US) Business Overview
  34. 8.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
  36. 8.6.5 MedImmune, LLC (US) Recent Developments
  37. 8.7 Mitsubishi Tanabe Pharma Corporation (Japan)
  38. 8.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
  39. 8.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
  40. 8.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
  42. 8.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
  43. 8.8 Panacea Biotec (India)
  44. 8.8.1 Panacea Biotec (India) Company Information
  45. 8.8.2 Panacea Biotec (India) Business Overview
  46. 8.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
  48. 8.8.5 Panacea Biotec (India) Recent Developments
  49. 8.9 Protein Sciences Corporation (US)
  50. 8.9.1 Protein Sciences Corporation (US) Company Information
  51. 8.9.2 Protein Sciences Corporation (US) Business Overview
  52. 8.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
  54. 8.9.5 Protein Sciences Corporation (US) Recent Developments
  55. 8.10 Serum Institute of India Pvt. Ltd. (India)
  56. 8.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
  57. 8.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
  58. 8.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
  60. 8.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
  61. 8.11 Astellas Pharma Inc. (Japan)
  62. 8.11.1 Astellas Pharma Inc. (Japan) Company Information
  63. 8.11.2 Astellas Pharma Inc. (Japan) Business Overview
  64. 8.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
  66. 8.11.5 Astellas Pharma Inc. (Japan) Recent Developments
  67. 8.12 Pfizer, Inc(US)
  68. 8.12.1 Pfizer, Inc(US) Company Information
  69. 8.12.2 Pfizer, Inc(US) Business Overview
  70. 8.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
  72. 8.12.5 Pfizer, Inc(US) Recent Developments
  73. 8.13 Merck & Co., Inc(US)
  74. 8.13.1 Merck & Co., Inc(US) Company Information
  75. 8.13.2 Merck & Co., Inc(US) Business Overview
  76. 8.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
  78. 8.13.5 Merck & Co., Inc(US) Recent Developments
  79. 8.14 Johnson & Johnson (US)
  80. 8.14.1 Johnson & Johnson (US) Company Information
  81. 8.14.2 Johnson & Johnson (US) Business Overview
  82. 8.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
  84. 8.14.5 Johnson & Johnson (US) Recent Developments
  85. 8.15 Sanofi Pasteur SA (France)
  86. 8.15.1 Sanofi Pasteur SA (France) Company Information
  87. 8.15.2 Sanofi Pasteur SA (France) Business Overview
  88. 8.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
  90. 8.15.5 Sanofi Pasteur SA (France) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multivalent Vaccines Value Chain Analysis
  2. 9.1.1 Multivalent Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multivalent Vaccines Production Mode & Process
  6. 9.2 Multivalent Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multivalent Vaccines Distributors
  9. 9.2.3 Multivalent Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst